reports
MBV International Limited: 1 director
A director at MBV International Limited sold 31,400,000 shares at 0.499HKD and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two ...
Kerur Holdings Ltd: 1 director
A director at Kerur Holdings Ltd bought 200,421 shares at 63.998ILS and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years c...
Man Group PLC : Form 8.3 - Mondi plc
Man Group PLC : Form 8.3 - Mondi plc FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser:Man Group PLC(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form...
EQS-News: Volta Medical Announces Late-Breaking TAILORED-AF Randomized...
EQS-News: Volta Medical SAS / Key word(s): Study Volta Medical Announces Late-Breaking TAILORED-AF Randomized Clinical Trial Results at Heart Rhythm 2024 in Boston, MA, USA 18.04.2024 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. Volta Medical Announces Late-Breaking TAILORED-AF Randomized Clinical Trial Results at Heart Rhythm 2024 in Boston, MA, USA Late-Breaking Randomized Clinical Trial Data to be presented by Professor Isabel Deisenhofer, German Heart Center Munich Department of Electrophysiology Demonstration of Volta AF-...
EQS-News: Volta Medical gibt die Ergebnisse seiner randomisierten klin...
EQS-News: Volta Medical SAS / Schlagwort(e): Studie Volta Medical gibt die Ergebnisse seiner randomisierten klinischen TAILORED-AF-Studie in einer Late-Breaker Präsentation auf der Heart Rhythm 2024 in Boston, USA bekannt 18.04.2024 / 14:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Volta Medical gibt die Ergebnisse seiner randomisierten klinischen TAILORED-AF-Studie in einer Late-Breaker Präsentation auf der Heart Rhythm 2024 in Boston, USA bekannt Late-Breaker Präsentation der Ergebnisse aus der randomisierten klinischen Studi...
Volta Medical annoncera les résultats de l’essai clinique randomisé TA...
Volta Medical SAS / Mot-clé(s) : Autres Volta Medical annoncera les résultats de l’essai clinique randomisé TAILORED-AF lors des sessions Late-Breaking du congrès Heart Rhythm 2024 à Boston, MA, États-Unis 18-Avr-2024 / 14:00 CET/CEST Volta Medical annoncera les résultats de l’essai clinique randomisé TAILORED-AF lors des sessions Late-Breaking du congrès Heart Rhythm 2024 à Boston, MA, États-Unis Les résultats « Late-Breaking » de l’essai clinique randomisé seront présentés par la Professeure Isabel Deisenhofer, du Département d’Electrophysiologie du Centre Allemand de Cardi...
EQS-News: SNP übernimmt Trigon Consulting und stärkt Premiumservices f...
EQS-News: SNP Schneider-Neureither & Partner SE / Schlagwort(e): Firmenübernahme SNP übernimmt Trigon Consulting und stärkt Premiumservices für Kunden und Partner 18.04.2024 / 14:00 CET/CEST Für den Inhalt der Mitteilung ist der Emittent / Herausgeber verantwortlich. Corporate News SNP übernimmt Trigon Consulting und stärkt Premiumservices für Kunden und Partner Beratungsspezialist für IT- und Business-Transformationen, Datenmigration und Digitalisierung wird mit Wirkung zum 1. Mai 2024 Teil der SNP-Gruppe Erweiterung und Stärkung des SNP-Kooperationsmodells, das Partn...
EQS-News: SNP acquires Trigon Consulting and strengthens premium servi...
EQS-News: SNP Schneider-Neureither & Partner SE / Key word(s): Takeover SNP acquires Trigon Consulting and strengthens premium services for customers and partners 18.04.2024 / 14:00 CET/CEST The issuer is solely responsible for the content of this announcement. Corporate News SNP acquires Trigon Consulting and strengthens premium services for customers and partners Consulting specialist for IT and business transformations, data migration and digitalization joins the SNP Group with effect from May 1, 2024 The move expands and strengthens the SNP go-to-market model, enab...
Lexicon Pharmaceuticals to Host 2024 Investor Day
Lexicon Pharmaceuticals to Host 2024 Investor Day Includes Business and Scientific Updates from Lexicon Executives and Leading Medical Experts in Hypertrophic Cardiomyopathy, Type 1 Diabetes and Diabetic Peripheral Neuropathic Pain THE WOODLANDS, Texas, April 18, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced that senior company executives will be joined by leading physicians at the Lexicon 2024 Investor Day on April 22, 2024. The event will be held in New York City from 9:00 a.m. to 12:00 p.m. ET. Business and scientific updates will be presented by Lonnel Coats, Lexicon’s c...
Allegro MicroSystems to Announce Fourth Quarter and Fiscal Year 2024 F...
Allegro MicroSystems to Announce Fourth Quarter and Fiscal Year 2024 Financial Results MANCHESTER, N.H., April 18, 2024 (GLOBE NEWSWIRE) -- Allegro MicroSystems, Inc. (Nasdaq: ALGM) today announced it plans to release financial results for its fourth quarter and fiscal year 2024 prior to the market open on Thursday, May 9, 2024. Following the press release, Vineet Nargolwala, President and Chief Executive Officer, and Derek D’Antilio, Senior Vice President and Chief Financial Officer, will host a conference call at 8:30 a.m. Eastern Time to discuss the Company’s results and business outlo...
Doman Building Materials Group Ltd. to Issue First Quarter 2024 Financ...
Doman Building Materials Group Ltd. to Issue First Quarter 2024 Financial Results May 9, 2024 THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, April 18, 2024 (GLOBE NEWSWIRE) -- Doman Building Materials Group Ltd. (“Doman” or “the Company”) (TSX: DBM) is pleased to announce that it will report its first quarter 2024 financial results for the period ended March 31, 2024, after market hours on Thursday, May 9, 2024. The Company will host ...
Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024
Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024 Conference call scheduled for 4:30 p.m. Eastern Time WALTHAM, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced it will hold a conference call on Thursday, May 2, 2024, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the first quarter of 2024. To participate in the confer...
Panbela Announces Poster Presentation at American Association for Canc...
Panbela Announces Poster Presentation at American Association for Cancer Research: Ivospemin/doxorubicin combination modulates polyamine metabolism to improve survival in murine ovarian cancer models MINNEAPOLIS, April 18, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA)(“Panbela”), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announces a poster presentation highlighting the results for ivospemin (SBP-101) as a polyamine metabolism modulator in ovarian cancer at the American Association fo...
Everest Group Names Dayforce a Leader in People Analytics Platform PEA...
Everest Group Names Dayforce a Leader in People Analytics Platform PEAK Matrix® Assessment 2024 Dayforce assessed for vision and capability, market impact MINNEAPOLIS and TORONTO, April 18, 2024 (GLOBE NEWSWIRE) -- , Inc. (NYSE: DAY; TSX: DAY), a global human capital management (HCM) leader that makes work life better, today announced it has been named a Leader in the by Everest Group. Dayforce was evaluated by Everest Group using PEAK Matrix, a proprietary framework that measures an organization’s ability to deliver products successfully and the impact it creates in the market. “In ...
GoHealth to Announce First Quarter 2024 Results on May 9, 2024
GoHealth to Announce First Quarter 2024 Results on May 9, 2024 CHICAGO, April 18, 2024 (GLOBE NEWSWIRE) -- (GoHealth) (NASDAQ: GOCO), a leading health insurance marketplace and Medicare-focused digital health company, announced that the company will release its first quarter 2024 financial results on the morning of May 9, 2024. Chief Executive Officer, Vijay Kotte, and Chief Financial Officer, Jason Schulz, will host a conference call and live audio webcast on the day of the release at 8:00 a.m. (ET) to discuss the results. A live audio webcast of the conference call will be available ...
Monopar Announces Radiopharma Presentation Selected for Society of Nuc...
Monopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual Meeting WILMETTE, Ill., April 18, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for cancer patients, today announced that its abstract on the preclinical data for its radiopharmaceutical program MNPR-101-Zr (MNPR-101 conjugated to zirconium-89) submitted to the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 Annual Meeting has been selected for a prese...
Dundee Precious Metals Annual Meeting of Shareholders to be Held May 8...
Dundee Precious Metals Annual Meeting of Shareholders to be Held May 8, 2024 TORONTO, April 18, 2024 (GLOBE NEWSWIRE) -- Dundee Precious Metals Inc. (TSX: DPM) (“DPM” or “the Company”) announces its Annual Meeting of Shareholders will be held on Wednesday, May 8, 2024, at 4 PM EDT via live audio webcast. Details of the Annual Meeting of Shareholders, including link to the audio webcast are as follows: Webcast date and timeWednesday, May 8, 20244 PM EDTWebcast link Replay Archive will be available on Meeting materialsAvailable on under Investor Centre About Dundee Precious Metal...
23andMe announces CEO’s intention to pursue a potential take-private
23andMe announces CEO’s intention to pursue a potential take-private SOUTH SAN FRANCISCO, Calif., April 18, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading human genetics and biopharmaceutical company, has been made aware that Anne Wojcicki, Chief Executive Officer, Co-Founder, and Chair of the Board of Directors of 23andMe, is considering making a proposal to acquire all of the outstanding shares of 23andMe that she does not currently own, as she stated in an amendment dated April 17, 2024 to her Schedule 13D filing with the Securities and Exchange Commission. Ms. Wo...
NV5 Awarded $19.5 Million Contract by the California Department of Tra...
NV5 Awarded $19.5 Million Contract by the California Department of Transportation, Expands Presence in Southern California HOLLYWOOD, Fla., April 18, 2024 (GLOBE NEWSWIRE) -- NV5 Global, Inc. (the “Company” or “NV5”) (Nasdaq: NVEE), NV5 Global, Inc. (the “Company” or “NV5”) (Nasdaq: NVEE), a provider of technology, conformity assessment, and consulting solutions, announced today that it has been awarded a three-year, $19.5 million construction inspection contract by the California Department of Transportation (Caltrans) District 7 in Northern Los Angeles County. Services to be delivered u...
AtriCure Announces Launch of the cryoSPHERE®+ Probe for Post-Operative...
MASON, Ohio--(BUSINESS WIRE)-- (), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it has launched the cryoSPHERE®+ cryoablation probe, leveraging new insulation technology to reduce freeze times by 25% versus AtriCure’s legacy cryoSHPERE® device. The product is currently in an extended limited launch period in the United States, with full launch expected by the end of the second quarter. “cryoSPHERE+ is a meaningful innovation that I believe will improve...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.